VRTX · Categories · Upgrades
VRTX - Analyst upgrades
Vertex Pharmaceuticals Incorporated (VRTX) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for VRTX
- Vertex Pharma upgraded by Maxim Group with a new price targetMaxim Group upgraded Vertex Pharma from Hold to Buy and set a new price target of $575.00
- Vertex Pharma upgraded by Oppenheimer with a new price targetOppenheimer upgraded Vertex Pharma from Perform to Outperform and set a new price target of $540.00
- Vertex Pharma upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded Vertex Pharma from Sector Perform to Outperform and set a new price target of $546.00
- Vertex Pharma upgraded by BernsteinBernstein upgraded Vertex Pharma from Mkt Perform to Outperform
- Vertex Pharma upgraded by Wolfe Research with a new price targetWolfe Research upgraded Vertex Pharma from Peer Perform to Outperform and set a new price target of $548.00
- Vertex Pharma upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Vertex Pharma from Equal-Weight to Overweight and set a new price target of $516.00
- Vertex Pharma upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Vertex Pharma from Market Perform to Outperform and set a new price target of $456.00
- Vertex Pharma upgraded by Wells Fargo with a new price targetWells Fargo upgraded Vertex Pharma from Equal Weight to Overweight and set a new price target of $460.00
- Vertex Pharma upgraded by Canaccord Genuity with a new price targetCanaccord Genuity upgraded Vertex Pharma from Sell to Hold and set a new price target of $424.00 from $408.00 previously
- Vertex Pharma upgraded by Canaccord GenuityCanaccord Genuity upgraded Vertex Pharma from Sell to Hold
- Vertex Pharma upgraded by Jefferies with a new price targetJefferies upgraded Vertex Pharma from Hold to Buy and set a new price target of $550.00 from $500.00 previously
- Vertex Pharma upgraded by Evercore ISI with a new price targetEvercore ISI upgraded Vertex Pharma from In-line to Outperform and set a new price target of $438.00
- Vertex Pharma upgraded by SVB Leerink with a new price targetSVB Leerink upgraded Vertex Pharma from Mkt Perform to Outperform and set a new price target of $374.00
- Vertex Pharma upgraded by Maxim Group with a new price targetMaxim Group upgraded Vertex Pharma from Hold to Buy and set a new price target of $325.00
- Vertex Pharma upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Vertex Pharma from Underweight to Equal-Weight and set a new price target of $250.00
- Vertex Pharmaceuticals upgraded by BMO Capital with a new price targetBMO Capital upgraded Vertex Pharmaceuticals from Market Perform to Outperform and set a new price target of $274.00 from $202.00 previously
- Vertex Pharmaceuticals upgraded by Robert W. Baird with a new price targetRobert W. Baird upgraded Vertex Pharmaceuticals from Neutral to Outperform and set a new price target of $252.00 from $220.00 previously
- Vertex Pharma upgraded by Robert W. Baird with a new price targetRobert W. Baird upgraded Vertex Pharma from Neutral to Outperform and set a new price target of $252.00 from $220.00 previously
- Vertex Pharmaceuticals upgraded by Baird with a new price targetBaird upgraded Vertex Pharmaceuticals from Neutral to Outperform and set a new price target of $252.00 from $220.00 previously